Evotec Reports Results of Phase II Proof-of-Concept Study with EVT 302

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ:
EVTC) today announced the results of a Phase II proof-of-concept
study investigating the potential of EVT 302, a reversible and highly
selective inhibitor of monoamine oxidase B (MAO-B), as an aid to
smoking cessation.

EVT 302 failed to demonstrate any significant improvement in the quit
rate compared with placebo. The combination of EVT 302 with a
nicotine replacement patch also failed to demonstrate any significant
benefit over nicotine replacement therapy (NRT) alone. The study was
well performed and the placebo quit rate was well within expectations
ensuring adequate power to demonstrate any treatment effect.
Throughout this study EVT 302 was well tolerated with subjects
experiencing very few treatment-related adverse events.

The study reported today was performed double blind in Germany with
414 otherwise healthy smokers who were motivated to quit smoking. The
study assessed whether 8 weeks treatment with EVT 302 resulted in an
increase in quit rate compared to placebo. The study also included a
comparison of EVT 302 added to NRT (21 mg patch once daily) vs NRT
alone to see if there was any additive benefit for the two treatments
taken together.

Dr Tim Tasker, Executive Vice President Clinical Development at
Evotec, commented: "We are disappointed with the results of this
proof-of-concept study which has failed to demonstrate any convincing
support for the use of EVT 302 as an aid to smoking cessation. Once a
full analysis of all the data is completed Evotec will re-assess the
future of EVT 302, given the overall potential of MAO-B-inhibitors in
a number of indications and the excellent safety profile demonstrated
by EVT 302 in this study."

Dr Werner Lanthaler, Chief Executive Officer of Evotec, added:
"Strict cost containment by focusing our pipeline and de-risking our
business according to the "Evotec 2012 - Action Plan to Focus and
Grow" is the right strategy also in light of this clinical outcome."

Contact Evotec AG:
Dr Werner Lanthaler
Chief Executive Officer
Phone: +49.(0)40.56081-242
werner.lanthaler@evotec.com

Anne Hennecke
SVP, Investor Relations & Corporate Communications
Phone: +49.(0)40.56081-286
anne.hennecke@evotec.com

Forward-Looking Statements
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. Such
forward-looking statements include, but are not limited to,
statements about our expectations and assumptions concerning future
reductions in operating expenses and cash burn, regulatory, clinical
and business strategies, the progress of our clinical development
programs and timing of the results of our clinical trials, strategic
collaborations and management's plans, objectives and strategies.
These statements are neither promises nor guarantees, but are subject
to a variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially
from those contemplated in these forward-looking statements. In
particular, the risks and uncertainties include, among other things:
risks that product candidates may fail in the clinic or may not be
successfully marketed or manufactured; risks relating to our ability
to advance the development of product candidates currently in the
pipeline or in clinical trials; our inability to further identify,
develop and achieve commercial success for new products and
technologies; competing products may be more successful; our
inability to interest potential partners in our technologies and
products; our inability to achieve commercial success for our
products and technologies; our inability to protect our intellectual
property and the cost of enforcing or defending our intellectual
property rights; our failure to comply with regulations relating to
our products and product candidates, including FDA requirements; the
risk that the FDA may interpret the results of our studies
differently than we have; the risk that clinical trials may not
result in marketable products; the risk that we may be unable to
successfully secure regulatory approval of and market our drug
candidates; and risks of new, changing and competitive technologies
and regulations in the U.S. and internationally.

The list of risks above is not exhaustive. Our most recent Annual
Report on Form 20-F, filed with the Securities and Exchange
Commission, and other documents filed with, or furnished to the
Securities and Exchange Commission, contain additional factors that
could impact our businesses and financial performance. We expressly
disclaim any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change in
our expectations or any change in events, conditions or circumstances
on which any such statement is based.

--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480; ISIN:
DE0005664809 ; Index: Prime All Share, CDAX, HDAX, MIDCAP, TECH All
Share;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Börse Berlin,
Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Düsseldorf,
Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische
Wertpapierbörse zu Hamburg,
Freiverkehr in Niedersächsische Börse zu Hannover, Regulierter Markt
in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2009. All rights reserved.